Drug Delivery Business

FDA approves BioStage’s esophageal device investigational new drug application

By

Biostage prices $8m offering for bioengineered organ implantsBiostage (NSDQ:BSTG) this week announced that its Cellspan Esophageal Implant investigational new drug application won FDA approval.

The Cellspan Esophageal Implant is designed to treat patients with end-stage esophageal disease that require segmental surgical resection to repair diseased tissue.

Biostage announced the first patient was treated with the esophageal implant in August 2017. The device was implanted in a 75-year old male patient who had a life-threatening cancerous mass in his chest.

Get the full story on our sister site, MassDevice.

IN CASE YOU MISSED IT

About Danielle Kirsh

Danielle Kirsh is an award-winning journalist and senior editor for Medical Design & Outsourcing, MassDevice, and Medical Tubing + Extrusion, and the founder of Women in Medtech and lead editor for Big 100. She received her bachelor's degree in broadcast journalism and mass communication from Norfolk State University and is pursuing her master's in global strategic communications at the University of Florida. You can connect with her on Twitter and LinkedIn, or email her at [email protected].